Cipla's US subsidiary partners with Qilu for exclusive licensing & supply of a Keytruda biosimilar (QL2107) in the US market. This strategic move aims to expand Cipla's oncology portfolio and improve access to affordable biologics.
Cipla is advancing with the merger of Inzpera Healthsciences. Shareholders and creditors have 30 days to submit any objections to the Tribunal regarding the proposed scheme, which otherwise will be presumed approved.
Cipla secured an exclusive licensing agreement with SBP Group for TQB2102, a promising HER2 bispecific ADC. This boosts Cipla's oncology pipeline for breast cancer patients across India, South Africa, and key emerging markets, enhancing access to innovative therapies.
Cipla's subsidiary InvaGen's USFDA inspection at its Central Islip facility is classified as Voluntary Action Indicated (VAI). This signals no immediate regulatory enforcement action, a positive development for operations.
Cipla's 60:40 joint venture, Aspergen India, has acquired 100% of Aspergen USA, a step-down subsidiary. This simplifies the group structure. Cipla's economic interest in Aspergen USA remains unchanged, making it a wholly-owned subsidiary of Aspergen India.